Event
Swiss Biotech Insight Event – “Bridging Preclinical to Clinical Development”
📅 Date: September 29, 2025
📍 Location: Lausanne, Switzerland
Viviana Agus,
Unit Manager, Cell Biology 2
Assay Development
Axxam at the “Bridging Preclinical to Clinical Development” event in Lausanne
Successful drug development requires closing the gap between preclinical insights and clinical outcomes. The event “Bridging Preclinical to Clinical Development” brings together experts in translational science, biomarkers, advanced modalities, and analytical innovation to discuss how to accelerate and de-risk therapeutic development.
Axxam continuously updates its scientific and technological toolbox to help clients move from promising biology to bioactive molecules—and ultimately toward safer, more effective clinical candidates.
Viviana Agus, our Cell Biology Unit Manager, is attending the event in Lausanne, exploring new approaches and tools to enhance the precision and translational value of discovery programs.
What the conference focuses on
The event highlights emerging concepts and technologies that strengthen the link between laboratory findings and clinical relevance, including:
- Holistic biomarkers and multi-OMICs strategies
- Advanced therapeutic modalities (RNA-targeting compounds, biologics, gene-modulating agents)
- High-resolution analytical methods for mechanism-of-action and safety profiling
- Approaches for integrated preclinical-to-clinical translational pipelines
- Tools for de-risking early-stage targets and molecules
These themes directly reinforce Axxam’s mission to deliver high-quality, reliable data that empowers informed decision-making.
Axxam’s role in bridging discovery and development
Our integrated platform supports clients with a continuum of solutions designed to reduce uncertainty and strengthen translational outcomes:
- Cellular and molecular biology expertise for understanding mechanism and pathway relevance
- Assay development and tailored functional, orthogonal, phenotypic, and high-content assays
- Target validation using disease-relevant systems, including iPSC-derived models
- Screening platforms (HTS, HCS, biophysical assays) to move from target to hit and from hit to lead
- Safety and toxicity-aligned in vitro studies that increase confidence before entering advanced stages
- Data-driven workflows that link biological function to clinically meaningful readouts
With a strong translational mindset, Axxam helps clients progress smarter, faster, and with greater confidence toward the clinic.
Collaborate with Axxam to de-risk your discovery pipeline
If you are working to accelerate your programs or exploring new therapeutic strategies, we would be pleased to discuss how Axxam can support your goals.